Tested Applications
| Positive FC detected in | mouse splenocytes |
Recommended dilution
| Application | Dilution |
|---|---|
| Flow Cytometry (FC) | FC : 0.5 ug per 10^6 cells in 100 ul suspension |
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
65662-1-TR targets CD4 in FC applications and shows reactivity with mouse samples.
| Tested Reactivity | mouse |
| Cited Reactivity | mouse |
| Host / Isotype | Rat / IgG2a |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
N/A Predict reactive species |
| Full Name | CD4 antigen |
| GenBank Accession Number | BC039137 |
| Gene Symbol | Cd4 |
| Gene ID (NCBI) | 12504 |
| RRID | AB_3743282 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P06332 |
| Storage Buffer | PBS with 0.09% sodium azide, pH 7.3. |
| Storage Conditions | Store at 2-8°C. Stable for one year after shipment. |
Background Information
CD4 is a 55-kDa transmembrane glycoprotein expressed on T helper cells, majority of thymocytes, monocytes, macrophages, and dendritic cells (PMID: 9304802; 12213222). CD4 is an accessory protein for MHC class-II antigen/T-cell receptor interaction. It plays an important role in T helper cell development and activation (PMID: 9539765; 3112582). CD4 serves as a receptor for the human immunodeficiency virus (HIV) (PMID: 9304802).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CD4 antibody 65662-1-TR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
Anti-Mouse CD4 (GK1.5) Rat Recombinant Antibody (65662-1-TR) has 4 total citations. It appears in Science Immunology (IF 16.4), Materials Today Bio (two articles, IF 11), and Veterinary Microbiology (IF 2.8). The research fields covered include cancer immunology and immunosuppression (DDX6-mediated dsRNA regulation), tumor-resident bacteria-driven prostate cancer therapy, cuproptosis-based nanoplatform immunotherapy, and swine vaccine immune responses using mouse models. Applications are primarily flow cytometry (FC), with species tested in mouse.
| Species | Application | Title |
|---|---|---|
Sci Immunol DDX6 induces immunosuppression in cancer by disrupting structural stability of endogenous double-stranded RNAs. | ||
Mater Today Bio 3-acetyl-11-keto-β-boswellic acid and chitosan-Ag nanoparticles for synergistic tumor-resident bacteria mediated prostate cancer therapy. | ||
Mater Today Bio Mitochondria-targeted cuproptosis-driven nanoplatform for synergistic photothermal/chemodynamic therapy and systemic antitumor immunotherapy. | ||
Vet Microbiol Synthetic peptide vaccines targeting SVA elicit robust protective immune responses in swine. |



